Clinical details of Professor Richard Scolyer’s experimental glioblastoma therapy have been published for the first time, showing clear evidence that combination immunotherapy can cross the blood–brain/tumour barrier.

The 2024 Australian of the Year has publicly shared regular updates about his progress since the shock diagnosis almost a year ago.

But the preprint report, which is yet to be published in a peer-reviewed journal, provides a detailed summary of treatment outcomes up to the 10-month mark.

The 57-year-old pathologist was diagnosed with a left temporal lobe grade 4 isocitrate dehydrogenase-wildtype, MGMT-unmethylated glioblastoma — a form associated with some of the poorest outcomes — in June 2023 shortly after an unexplained seizure while traveling in Poland.